We examined the effects of tumour necrosis factor α (TNFα) and interferon γ (IFNγ) on the production of collagen by human infant foreskin fibroblasts. Collagen synthesis was maintained in the presence of IGF-I so that cytokine effects could be examined in the absence of serum. TNFα inhibited IGF-I-maintained collagen production in a dose-dependent manner. Maximal suppression of 50% was attained at a concentration of 7·5 ng/ml. IFNγ also suppressed collagen accumulation in IGF-I-maintained cells, with a maximal inhibition to 55% at 375 U/ml. The rate of collagen formation relative to total protein production for secreted proteins was calculated. This value decreased from 10·3% for IGF-I-cultured cells to 6·2% and 8·4% with the inclusion of TNFα and IFNγ respectively, indicating that inhibition was selective for collagen. TNFα (5 ng/ml) and IFNγ (250 U/ml) together suppressed IGF-I-maintained collagen production to approximately 35%, with a decrease from 10·3% to 2·9% in collagen production relative to total protein. The inclusion of a serum-free period prior to the addition of TNFα to the cultures resulted in a further inhibition to 15% of control. This increase in inhibition was not seen if dexamethasone was present in the serum-free period prior to cytokine addition. These data showed that IGF-Imaintained collagen formation is suppressed by the proinflammatory cytokines TNFα and IFNγ, and that these interactions are influenced by dexamethasone. Proinflammatory cytokines interact in a complex manner with other serum factors to modulate IGF-I-stimulated extracellular matrix production and may have important roles in regulating tissue repair.
Journal of Endocrinology (1995) 147, 167–176
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 1 | 0 | 0 |
| PDF Downloads | 4 | 0 | 0 |
Online ISSN: 1479-6805
Print ISSN: 0022-0795
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
